In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscape.

From the US Most Favored Nation (MFN) policy and Germany's Medical Research Act to surprising developments in Japan's pricing thresholds, Nikhil breaks down how these changes are reshaping pricing and reimbursement strategies worldwide.

The conversation covers emerging regional patterns across Europe, North America, and Asia, with particular focus on three key themes: cost containment measures, value-based innovation recognition, and increasing transparency requirements. Nikhil also addresses the practical challenges pharmaceutical companies face as they navigate stricter evidence requirements, lower price tolerance, and greater global interconnectedness.

This episode references Nikhil's 'In the Loop' email newsletter and 'Navigating the Waves' blog, which he authors with his team. Find out more and subscribe on these links:

https://accessinfinity.com/policy-intelligence/subscribe-to-in-the-loop/

https://accessinfinity.com/news-resources/

and filter 'policy insights'.

Send us a text

In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this episode unpacks what pharma companies need to know about preparing for an uncertain policy landscape through strategic scenario planning.

Useful resources referenced in this episode:

You can download the article 'Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future' here.

Details of the CELforPharma course 'Understanding Pharma Market Access in the US' are available on the CELforPharma website here.

Send us a text

In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease.

Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies prove value in ultra-rare diseases. From multi-domain endpoints and visual evidence to payment-by-results models, this episode reveals why traditional HTA frameworks fall short for orphan drugs and how early collaboration between pricing, market access, and clinical teams is essential for success.

Isabel has authored a blog on this topic, which you can read here: accessinfinity.com/blogs/breaking-through-barriers-how-innovation-is-revolutionising-orphan-drug-development.

Send us a text